Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: Outcomes in 102 patients

2010 ◽  
Vol 41 (5) ◽  
pp. 593-598 ◽  
Author(s):  
Michael K. Hehir ◽  
Ted M. Burns ◽  
Joshua Alpers ◽  
Mark R. Conaway ◽  
Michael Sawa ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Myasthenia Gravis ◽  
Achr Antibody

scholarly journals Effective Early Treatment of AChR Antibody-Positive Myasthenia Gravis with Rituximab; the Experience from a Neuroimmunology Clinic in a Developing Country

2021 ◽  
Vol 13 ◽  
pp. 117957352110160
Author(s):  
Thomas Mathew ◽  
Kurian Thomas ◽  
Saji K John ◽  
Shruthi Venkatesh ◽  
Raghunandan Nadig ◽  
...  
Keyword(s):  
Observational Study ◽  
Myasthenia Gravis ◽  
Treatment Option ◽  
Early Treatment ◽  
Early Stage ◽  
Tertiary Care ◽  
Response To Treatment ◽  
Myasthenic Crisis ◽  
Achr Antibody ◽  
Significant Difference

Background: Rituximab is reserved for treating refractory myasthenia gravis (MG) patients. Here we report our experience with rituximab in AChR antibody positive generalized MG (gMG) and impending myasthenic crisis (IMC). Methods: This retrospective, observational study, conducted at a tertiary care, neuroimmunology clinic, analyzed the data of patients with AChR antibody positive gMG, treated with rituximab between 1st January 2016 and 30th October 2018. Results: Eleven patients with AChR antibody positive gMG received rituximab. Mean age of the cohort was 50.54 ± 18.71 years with 9 males. Seven out of 11 patients received rituximab in the early stage (<2 years from onset) and had good response to treatment. Four of the 5 patients with IMC improved with rituximab alone. In the 10 patients who regularly followed up, there was a significant difference between the QMG scores at baseline and at 1, 2, 6, 12, and 18 months ( P < .0001). Conclusion: Rituximab appears to be a potentially effective early treatment option for AChR antibody positive generalized MG and impending myasthenic crisis.

scholarly journals The Effect of Plasmapheresis on Post-Thymectomy Ocular Dysfunction

1981 ◽  
Vol 8 (2) ◽  
pp. 169-172 ◽  
Author(s):  
C.W. Olanow ◽  
A.D. Roses ◽  
J.W. Fay
Keyword(s):  
Myasthenia Gravis ◽  
Clinical Improvement ◽  
Antibody Titer ◽  
Clinical State ◽  
Achr Antibody ◽  
The Individual ◽  
Thymic Factor ◽  
Ocular Signs

SUMMARY:Five myasthenia gravis patients with post-thymectomy residual ocular signs were treated with plasmapheresis. Despite a significant reduction in AChR antibody titer, there was no clinical improvement. Subsequently, there was a dramatic response to prednisone. The AChR antibody titer did not correlate with the clinical state of the individual patient. It is suggested that plasmapheresis may operate by removing a thymic factor and that prednisone acts by a different mechanism.

Anti AChR antibody: Relevance to diagnosis and clinical aspects of myasthenia gravis

1988 ◽  
Vol 9 (2) ◽  
pp. 141-145 ◽  
Author(s):  
R. Mantegazza ◽  
D. Pareyson ◽  
F. Baggi ◽  
P. Romagnoli ◽  
D. Peluchetti ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Clinical Aspects ◽  
Achr Antibody
Sign in / Sign up

Export Citation Format

Share Document